With grit and integrity, we advance novel therapies for individuals with chronic neutropenic disorders
Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we aim to bring innovative treatments to patients with chronic neutropenic disorders.
Our lead product candidate, mavorixafor, is designed to enable mobilization of immune cells from the bone marrow into the bloodstream to improve immune system function.
August 08, 2022
X4 Pharmaceuticals to Present at Canaccord Genuity’s 42nd...
August 04, 2022
X4 Pharmaceuticals Reports Second Quarter 2022 Financial...
X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.